Oscar Health, Inc. Issues Regulation FD Disclosure Ahead of Raymond James Conference
Key Points from the Report:
- Oscar Health, Inc. (NYSE: OSCR) has filed a Form 8-K with the SEC on March 2, 2026, under Item 7.01 (Regulation FD Disclosure).
- The company announced its participation in the 2026 Raymond James Institutional Investors Conference taking place on March 2, 2026.
- At the conference, Oscar Health will reaffirm its full-year 2026 financial guidance, which was previously disclosed in the press release for Q4 and full-year 2025 results (dated February 10, 2026).
Price-Sensitive Information and Shareholder Considerations:
- Reaffirmation of Guidance: Oscar Health’s public reaffirmation of its 2026 guidance is a significant event for shareholders and investors. Such reaffirmation signals management’s confidence in the company’s outlook, which can impact investor sentiment and potentially affect share price.
- Forward-Looking Statements: The company’s statements include forward-looking information about expected financial performance and upcoming events. Oscar explicitly cautions that these statements are subject to risks, uncertainties, and assumptions. Investors are advised to review the “Risk Factors” section in Oscar Health’s Annual Report on Form 10-K for the year ended December 31, 2025, and other SEC filings for a more comprehensive understanding of these risks.
- No Amendments or Written/Soliciting Materials: The 8-K filing is not an amendment and does not include written communications or soliciting materials pursuant to relevant SEC rules. There are also no tender offers or pre-commencement communications reported.
Additional Details:
- Company Details: Oscar Health, Inc. is incorporated in Delaware, with principal executive offices at 75 Varick Street, 5th Floor, New York, NY 10013. The company’s telephone number is (646) 403-3677.
- Security Details: The company’s Class A Common Stock (\$0.00001 par value per share) is listed on the New York Stock Exchange under the symbol “OSCR”.
- Signatory: The filing is signed by Adam McAnaney, Chief Legal Officer, as of March 2, 2026.
- Emerging Growth Company Status: Oscar Health is not classified as an emerging growth company, and has not elected to use the extended transition period for complying with new or revised accounting standards.
Potential Share Price Impact:
- The reaffirmation of full-year 2026 guidance at a major investor conference is likely to be viewed as positive by the market, as it suggests continuity and confidence in business execution. However, investors should be aware this is not new guidance, but confirmation of previously announced targets.
- Any deviation from expected performance or guidance, or material changes during the conference, would be considered price-sensitive. At this time, no new material information or changes are reported in this 8-K.
Cautionary Note:
- Forward-looking statements in this report are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond the company’s control. Management expresses that expectations are reasonable as of the date of the report but highlights that new factors may arise that could materially affect results.
Disclaimer: This article is based solely on information disclosed in Oscar Health, Inc.’s Form 8-K filed on March 2, 2026. It does not constitute investment advice. Investors should review Oscar’s Annual Report and other SEC filings for comprehensive risk disclosures and consult their own financial advisors before making investment decisions.
View Oscar Health, Inc. Historical chart here
